A5005928906- HIV/AIDS Research and Interventions
- HIV/AIDS drug development and treatment
- HIV Research and Treatment
- Pharmacological Effects and Toxicity Studies
- Reproductive Health and Contraception
- HIV-related health complications and treatments
- Pneumocystis jirovecii pneumonia detection and treatment
- Pregnancy and Medication Impact
- Hepatitis C virus research
- HIV, Drug Use, Sexual Risk
- Antibiotic Use and Resistance
- LGBTQ Health, Identity, and Policy
- Sexual function and dysfunction studies
- Drug Transport and Resistance Mechanisms
- Global Maternal and Child Health
- Systemic Lupus Erythematosus Research
- Blood groups and transfusion
- Pharmaceutical Practices and Patient Outcomes
- Antibiotic Resistance in Bacteria
- Hepatitis B Virus Studies
- Sexuality, Behavior, and Technology
- Medication Adherence and Compliance
- Barrier Structure and Function Studies
- Dialysis and Renal Disease Management
- Malaria Research and Control
University of Nebraska Medical Center
2016-2025
Nebraska Medical Center
2014-2024
University of Nebraska at Omaha
2020-2023
Northwestern University
2002-2014
Center for Global Health
2011-2014
IS practice
2010-2014
Northwestern Memorial Hospital
2000-2013
University of Missouri
2011
University of Rochester
2011
Johns Hopkins University
2011
Hepatitis C virus (HCV) infection is increasing among pregnant women because of the opioid epidemic, yet there are no interventions to reduce perinatal HCV transmission or treat during pregnancy. Physiological changes in pregnancy alter pharmacokinetics some medications; thus, our aim was compare pharmacokinetic parameters ledipasvir 90 mg plus sofosbuvir 400 with non-pregnant women.This an open-label, phase 1 study genotype and their infants. A reference group who had participated studies...
Abstract Background Human immunodeficiency virus (HIV) pre-exposure prophylaxis (PrEP) substantially reduces the risk of HIV acquisition, yet significant barriers exist to its prescription and use. Incorporating pharmacists in PrEP care process may help increase access services. Methods Our pharmacist-led program (P-PrEP) included from a university-based clinic, community pharmacy, 2 community-based clinics. Through collaborative practice agreement, conducted visits with potential candidates...
Journal Article Pharmacist participation in medical rounds reduces medication errors Get access Kimberly K. Scarsi, Pharm.D., Pharm.D. Clinical Department of Pharmacy, Northwestern Memorial Hospital, Chicago, IL Address correspondence to Dr. Scarsi at the Feinberg LC-700, 251 East Huron Street, 60611 (kscarsi@nmh.org). Search for other works by this author on: Oxford Academic Google Scholar Michael A. Fotis, B.S.Pharm., B.S.Pharm. Manager Drug Policy and Staff Development Gary Noskin, M.D....
We conducted a study of minocycline to assess its safety, tolerability, and efficacy for the treatment HIV-associated cognitive impairment.
Background. Levonorgestrel subdermal implants are preferred contraceptives with an expected failure rate of <1% over 5 years. We assessed the effect efavirenz- or nevirapine-based antiretroviral therapy (ART) coadministration on levonorgestrel pharmacokinetics.
Objectives: The aim of the study was to compare intraindividual plasma and intracellular peripheral blood mononuclear cell (PBMC) pharmacokinetics tenofovir (TFV) its metabolite, TFV-diphosphate (TFV-DP) in patients switched from a fixed-dose combination (FDC) tablet TFV disoproxil fumarate (TDF)/emtricitabine (FTC)/elvitegravir (EVG)/cobicistat (COBI) FDC containing alafenamide (TAF)/FTC/EVG/COBI. Design: A single-arm, prospective, nonrandomized, cross-over, pharmacokinetic receiving...
Abstract Background Human immunodeficiency virus (HIV) viral suppression (VS) decreases morbidity, mortality, and transmission risk. Methods The Patient-centered HIV Care Model integrated community-based pharmacists with medical providers required them to share patient clinical information, identify therapy-related problems, develop action plans. Proportions adherent antiretroviral therapy (proportion of days covered [PDC] ≥90%) virally suppressed (HIV RNA &lt;200 copies/mL), before...
Objectives: The primary objective of this study was to characterize the pharmacokinetics etonogestrel (ENG) released from a contraceptive implant in Ugandan women living with HIV who were receiving efavirenz (EFV) or nevirapine (NVP)-based antiretroviral therapy (ART), compared ART-naive over 24 weeks. Design: Nonrandomized, parallel-group three arms: ART-naive, NVP, EFV-based ART (N = 20/group). Methods: Sparse pharmacokinetic sampling ENG, EFV performed at screening, entry, and then 1, 4,...
Introduction Contraception is often required for management and population control purposes in group-housed free-roaming non-human primates. Long-acting reversible contraceptives, including subdermal progestin-releasing implants, are preferred as they eliminate challenges associated with frequent administration. Etonogestrel (ENG)-releasing implants long-acting a minimum of 3 years, commercially available human use Implanon ® or Nexplanon . Methods A retrospective analysis was performed...
Abstract Five long‐acting (LA) antiretrovirals (ARVs) are currently available in a limited number of countries worldwide for HIV‐1 prevention or treatment—cabotegravir, rilpivirine, lenacapavir, ibalizumab, and dapivirine. Implementing use LA ARVs into routine clinical practice requires significant changes to the current framework prevention, treatment, service provision. Given novelty, complexity, interdisciplinary requirements needed safely optimally utilize ARVs, consensus recommendations...
Background To date, antiretroviral therapy (ART) guidelines and programs in resource-limited settings (RLS) have focused on 1st- 2nd-line (2 L) therapy. As approach a decade of implementation, policy regarding access to 3rd-line (3 ART is needed. We aimed examine the impact maintaining patients failing 2 L accumulation protease (PR) mutations. Methods Findings From 2004–2011, Harvard/APIN PEPFAR Program provided >100,000 people Nigeria. Genotypic resistance testing was performed subset...
To investigate the intraindividual pharmacokinetics (PKs) of total (protein bound plus unbound) and unbound lopinavir/ritonavir (LPV/RTV) to assess whether pediatric formulation (100 mg/25 mg) can overcome any pregnancy-associated changes.